Quarterly results for Alivus Life Sciences Ltd

Alivus Life Sciences Limited – Q1 FY26 Results Summary
Announcement Date: August 1, 2025

• Revenue: ₹6,018 million, up 2.2% YoY from ₹5,886 million in Q1 FY25; down from ₹6,495 million in Q4 FY25.
• EBITDA: Approximately ₹1,813 million; EBITDA margin at 29.7% (vs. 27.8% in Q1 FY25).
• Net Profit: ₹1,215 million, up 9% YoY; net profit margin at 19.9%.
• Earnings Per Share (Basic): ₹9.91 (Q1 FY25: ₹9.10).
• Auditor’s Opinion: Clean limited review report with no qualifications.
• Segment: Single segment – Active Pharmaceutical Ingredient (API).
• Inventory: Significant reduction in inventory changes YoY (₹14 million vs. ₹414 million), indicating improved inventory management.
• ESOP: 652,831 stock options outstanding as of June 30, 2025.
• Corporate Activity: No reported capital expenditure, acquisitions, impairments, or restructuring.
• Financials: Consolidated results prepared under Ind AS, approved by the Board on August 1, 2025.

No changes in accounting policies or material adjustments were reported.

Note: This is an AI generated summary of the results. There may be inaccuracies in the summary. Please refer to the original document before making investment decisions.